Venus Remedies Hits New 52-Week High of Rs.808.5, Marking Significant Milestone

Stock Performance and Market Context

On 4 Dec 2025, Venus Remedies opened with a gap up of 4.94%, signalling robust buying interest at the start of the trading session. The stock touched an intraday high of Rs.808.5, marking its highest price in the past year and all-time. Despite this peak, the stock experienced some volatility, dipping to an intraday low of Rs.731.95, representing a 5% range within the day. The closing price reflected a slight decline of 0.32% from the day’s high, underperforming the Pharmaceuticals & Biotechnology sector by 4.86% on the day.

Venus Remedies is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates a strong upward trend and sustained investor confidence over multiple time horizons.

Meanwhile, the broader market environment showed resilience. The Sensex, after an initial negative opening down by 119.25 points, rebounded to close 0.21% higher at 85,284.08, just 1.03% shy of its own 52-week high of 86,159.02. Mid-cap stocks led the market gains, with the BSE Mid Cap index rising by 0.25%, providing a supportive backdrop for Venus Remedies’ performance.

Financial Metrics Underpinning the Rally

Venus Remedies’ stock price trajectory aligns with its robust financial results over recent periods. The company reported a net profit growth of 473.5% in the September 2025 quarter, continuing a positive earnings trend for four consecutive quarters. The latest six-month profit after tax (PAT) stood at Rs.29.73 crores, reflecting a growth rate of 528.54%. Profit before tax excluding other income (PBT less OI) for the quarter was Rs.24.78 crores, showing an exceptional increase of 2073.68%.

Return on capital employed (ROCE) for the half-year period reached 13.99%, the highest recorded for the company, while return on equity (ROE) was reported at 10.5%. These profitability metrics indicate efficient utilisation of capital and equity, contributing to the stock’s appeal in valuation terms.

Venus Remedies maintains a low debt-to-equity ratio averaging zero, highlighting a conservative capital structure that may appeal to risk-conscious investors. The stock’s price-to-book value ratio stands at 1.7, suggesting a valuation that is reasonable relative to its peers and historical averages.

Over the past year, Venus Remedies has delivered a total return of 134.93%, significantly outpacing the Sensex’s 5.35% return during the same period. Profit growth over the year has been recorded at 183%, with a price-to-earnings-to-growth (PEG) ratio of 0.1, indicating that the stock’s price movement is supported by strong earnings expansion.

Stock Price History and Volatility

The stock’s 52-week low was Rs.272.2, illustrating the substantial appreciation Venus Remedies has experienced over the last year. The current high of Rs.808.5 represents nearly a threefold increase from that low point. This price movement reflects both the company’s operational progress and the broader sectoral tailwinds in Pharmaceuticals & Biotechnology.

Despite the recent rally, the stock has shown some short-term price fluctuations. After three consecutive days of gains, the stock price saw a minor pullback today. Such volatility is common in stocks experiencing rapid appreciation and may reflect profit-taking or market sentiment shifts.

Market Position and Shareholding Insights

Venus Remedies operates within the Pharmaceuticals & Biotechnology sector, a segment that has shown resilience and growth potential in recent years. The company’s market capitalisation grade is rated at 4, reflecting its mid-cap status. Despite its size and performance, domestic mutual funds currently hold no stake in the company. This absence of mutual fund ownership may indicate a cautious stance from institutional investors or a reflection of the stock’s valuation at current levels.

The company’s consistent quarterly results and strong profitability metrics have contributed to its market-beating performance over the long term. Venus Remedies has outperformed the BSE500 index over the last three years, one year, and three months, highlighting its sustained growth trajectory relative to a broad market benchmark.

Summary of Key Price and Performance Data

• New 52-week and all-time high: Rs.808.5

• Intraday price range on 4 Dec 2025: Rs.731.95 to Rs.808.5

• Yearly price range: Rs.272.2 (52-week low) to Rs.808.5 (52-week high)

• One-year return: 134.93%

• Sensex one-year return: 5.35%

• Latest six-month PAT: Rs.29.73 crores

• ROCE (half-year): 13.99%

• ROE: 10.5%

• Price-to-book value: 1.7

• Debt-to-equity ratio: 0 (average)

Venus Remedies’ achievement of a new 52-week high at Rs.808.5 marks a significant milestone in its stock market journey. Supported by strong earnings growth, solid returns on capital, and a favourable technical setup, the stock’s momentum reflects the company’s underlying financial strength and sectoral tailwinds.

While the stock experienced a minor pullback after three days of gains, its position above all major moving averages and substantial year-on-year returns underscore its robust market standing. The broader market’s positive trend, with the Sensex nearing its own 52-week high, adds further context to Venus Remedies’ performance within the Pharmaceuticals & Biotechnology sector.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →